Lessons from next generation influenza vaccines for inflammatory disease therapies

Daniel H. Zimmerman; R. E. Carambula; J. Ciemielewski; K. S. Rosenthal

doi:10.1016/j.intimp.2019.105729

Lessons from next generation influenza vaccines for inflammatory disease therapies

Daniel H. Zimmerman, R. E. Carambula, J. Ciemielewski, K. S. Rosenthal

Research output: Contribution to journal › Review article › peer-review

Abstract

Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic ‘strains’ and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.

Original language	English (US)
Article number	105729
Journal	International Immunopharmacology
Volume	74
DOIs	https://doi.org/10.1016/j.intimp.2019.105729
State	Published - Sep 2019
Externally published	Yes

Keywords

Immunomodulation
Influenza
Rheumatoid arthritis
T cells
Vaccine therapy

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pharmacology

Access to Document

10.1016/j.intimp.2019.105729

Fingerprint Dive into the research topics of 'Lessons from next generation influenza vaccines for inflammatory disease therapies'. Together they form a unique fingerprint.

Cite this

@article{3e6a4e34333f4d91a73b270f641fafdd,

title = "Lessons from next generation influenza vaccines for inflammatory disease therapies",

abstract = "Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic {\textquoteleft}strains{\textquoteright} and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.",

keywords = "Immunomodulation, Influenza, Rheumatoid arthritis, T cells, Vaccine therapy",

author = "Zimmerman, {Daniel H.} and Carambula, {R. E.} and J. Ciemielewski and Rosenthal, {K. S.}",

note = "Funding Information: Research reported in this publication was supported by the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) of USA under award number R44 AR063504-02A1 for DH Zimmerman. ",

year = "2019",

month = sep,

doi = "10.1016/j.intimp.2019.105729",

language = "English (US)",

volume = "74",

journal = "International Immunopharmacology",

issn = "1567-5769",

publisher = "Elsevier",

}

TY - JOUR

T1 - Lessons from next generation influenza vaccines for inflammatory disease therapies

AU - Zimmerman, Daniel H.

AU - Carambula, R. E.

AU - Ciemielewski, J.

AU - Rosenthal, K. S.

N1 - Funding Information: Research reported in this publication was supported by the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) of USA under award number R44 AR063504-02A1 for DH Zimmerman.

PY - 2019/9

Y1 - 2019/9

N2 - Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic ‘strains’ and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.

AB - Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic ‘strains’ and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.

KW - Immunomodulation

KW - Influenza

KW - Rheumatoid arthritis

KW - T cells

KW - Vaccine therapy

UR - http://www.scopus.com/inward/record.url?scp=85068269443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068269443&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2019.105729

DO - 10.1016/j.intimp.2019.105729

M3 - Review article

C2 - 31280056

AN - SCOPUS:85068269443

VL - 74

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

M1 - 105729

ER -

Lessons from next generation influenza vaccines for inflammatory disease therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this